InsidersTradesSigma
Follow the 毕得医药 stock price and the full directors' dealings record of the company, a publicly traded company based in China. Shares trade on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 毕得医药 has published 8 public disclosures. Market capitalisation: €5.8bn. The latest transaction was reported on 7 September 2026 (Sale). Among the most active insiders: 戴岚. Every trade is accessible without an account.
8
Insider Decl.
n/a
Thresholds
€140,710
2 ops.
Buy Volume
€882,485
6 ops.
Sell Volume
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,082 of 29,064 companies
51.0
score / 100
Value35
Quality67
FCF yld0.1%
Earn yld2.6%
EV/EBITDA25.8x
ROE9.1%
Gross mgn45%
Net mgn11%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 7 September 2026
Declarations8 total
8 of 8 declarations
关于 毕得医药
毕得医药是一家在上海证券交易所上市的医疗保健和制药领域的公司。它专注于创新医药产品的开发和商业化。